✦ LIBER ✦

MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II non-small cell lung cancer (NSCLC): from proof-of-concept to phase III trial (MAGRIT)

✍ Scribed by Eisen, T.; Vansteenkiste, J.; Zielinski, M.; Linder, A.; Dahabreh, J.; Jassem, J.; Passlick, B.; Debruyne, C.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

102PD MAGE-A3 ANTIGEN-SPECIFIC CANCER IM

✍ Passlick, B.; Vansteenkiste, J.; Zielinski, M.; Linder, A.; Dahabreh, J.; Esteba 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 44 KB

9021 Preliminary results of MAGE-A3 expr

✍ Zielinski, M.; Laskowski, U.; Bieselt, R.; Reck, M.; Strausz, J.; Perdeus, J.; P 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 66 KB

6514 ORAL Adjuvant therapy in stage IB/I

✍ Vansteenkiste, J.; Zielinski, M.; Linder, A.; Dahabre, J.; Esteban, E.; Malinows 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 59 KB